IN a world where chocolate bars are now packed with protein and the word ‘natural’ is often stamped across ultra-processed snacks, it can be tricky to know what to buy when browsing supermarket ...
Scholar Rock aims for a 2025 launch of apitegromab in SMA, expecting $2 billion in global revenue and significant growth from upcoming trials and favorable data.
Potential to be the first targeted therapy for GBS: Successful pivotal Phase 3 trial showed ANX005 helped patients get better sooner with rapid improvement in muscle strength and more complete ...